Soleimani Sasani Mahboubeh, Moradi Yeganeh
Shahid Beheshti University, Tehran, Iran.
Department of Biotechnology Engineering, Faculty of Medical Engineering, Shahab Danesh University, Qom, Iran.
Avicenna J Med Biotechnol. 2024 Jul-Sep;16(3):137-145. doi: 10.18502/ajmb.v16i3.15739.
Rheumatoid Arthritis (RA) is an autoimmune disease and chronic inflammatory disorder that affects joints and causes inflammation, pain, stiffness, and eventually progressive joint destruction. Approximately 1% of the world's population is estimated to suffer from RA, and if this disease is left untreated, it can lead to severe disability. Despite all the efforts and advances made by professionals in the field, there is currently no definitive treatment for RA, and most treatment strategies are aimed at relieving symptoms and improving patients' quality of life. One of the most promising current approaches is the use of recombinant proteins that target specific signaling pathways involved in the development of RA to alleviate symptoms and slow the progression of the disease. This article discusses the genetic and immunological factors that influence the development of RA, recombinant proteins, methods of using these proteins, approved drugs, and side effects associated with treating RA.
类风湿性关节炎（RA）是一种自身免疫性疾病和慢性炎症性疾病，会影响关节并导致炎症、疼痛、僵硬，最终导致关节进行性破坏。据估计，全球约1%的人口患有RA，如果这种疾病得不到治疗，可能会导致严重残疾。尽管该领域的专业人员做出了种种努力并取得了进展，但目前尚无针对RA的确定性治疗方法，大多数治疗策略旨在缓解症状并改善患者的生活质量。当前最有前景的方法之一是使用重组蛋白，这些蛋白靶向参与RA发病的特定信号通路，以减轻症状并减缓疾病进展。本文讨论了影响RA发病的遗传和免疫因素、重组蛋白、使用这些蛋白的方法、获批药物以及与治疗RA相关的副作用。
